Corvus PharmaceuticalsCRVS
CRVS
About: Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
Employees: 31
0
Funds holding %
of 7,345 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
145% more call options, than puts
Call options by funds: $4.73M | Put options by funds: $1.93M
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
13% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 23
2% more funds holding
Funds holding: 85 [Q4 2024] → 87 (+2) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
5.5% less ownership
Funds ownership: 58.72% [Q4 2024] → 53.23% (-5.5%) [Q1 2025]
43% less capital invested
Capital invested by funds: $202M [Q4 2024] → $115M (-$86.5M) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$11
111%
upside
Avg. target
$11
111%
upside
High target
$11
111%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Mizuho Graig Suvannavejh | 111%upside $11 | Outperform Maintained | 20 May 2025 |
Financial journalist opinion
Based on 4 articles about CRVS published over the past 30 days
Positive
Seeking Alpha
2 days ago
Corvus Pharmaceuticals: Positive Phase 1 Soquelitiinb Trial Data Brings 2025 Catalysts
Company's soquelitinib shows promising phase 1 results in moderate-to-severe atopic dermatitis, with key phase 1 and phase 2 catalysts expected before the end of 2025. The drug's versatility targets both cancer and autoimmune disorders, expanding its market potential beyond oncology into other large market indications. Financial runway is limited to Q4 2026, with potential dilution risk if additional funds are raised after upcoming clinical catalysts.
Neutral
Seeking Alpha
6 days ago
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Leiv Lea - Chief Financial Officer Richard A. Miller - Co-Founder, President, CEO & Chairman of the Board Conference Call Participants Aydin Huseynov - Ladenburg Thalmann & Co. Inc., Research Division Jeffrey Michael Jones - Oppenheimer & Co. Inc., Research Division Zack Kubow - Real Chemistry, Inc. Operator Good afternoon, everyone.
Positive
The Motley Fool
1 week ago
Corvus (CRVS) Q2 Loss Beats Estimates
Corvus (CRVS) Q2 Loss Beats Estimates
Neutral
GlobeNewsWire
1 week ago
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results
Soquelitinib data from cohort 3 of atopic dermatitis Phase 1 clinical trial demonstrates earlier and deeper responses compared to cohorts 1-2 along with clinically meaningful reduction in itch as early as day 8
Positive
24/7 Wall Street
2 months ago
3 Penny Stocks Wall Street Sees With 243% Upside
“The Next NVIDIA” Could Change Your Life NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.
Neutral
GlobeNewsWire
2 months ago
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2 All three cohorts show separation from placebo with statistically significant difference from placebo at day 28 Cohort 3 demonstrates clinically meaningful reduction in itch as early as day 8 Enrollment initiated in extension cohort study exploring the same cohort 3 dose (200 mg BID) for a longer 8-week treatment period SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.
Neutral
GlobeNewsWire
2 months ago
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the 2025 Jefferies Global Healthcare Conference, which is being held in New York, NY. The presentation will be on Thursday, June 5 from 9:20-9:50 am ET.
Positive
Benzinga
3 months ago
Why Is Corvus Pharmaceuticals Stock Soaring On Friday?
Corvus Pharmaceuticals, Inc. CRVS on Thursday released new interim data from the Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.
Neutral
Seeking Alpha
3 months ago
Corvus Pharmaceuticals, Inc. (CRVS) Q1 2025 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, Investor Relations Leiv Lea - Chief Financial Officer Richard Miller - Chief Executive Officer Conference Call Participants Aydin Huseynov - Ladenburg Graig Suvannavejh - Mizuho Securities Li Watsek - Cantor Jeff Jones - Oppenheimer Roger Song - Jefferies Sean Lee - H.C. Wainwright Operator Good afternoon, everyone.
Neutral
GlobeNewsWire
3 months ago
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results
Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2
Charts implemented using Lightweight Charts™